| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | cdtA |
| Uniprot No | Q46668 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-258aa |
| 氨基酸序列 | CSSGKNKAYLDPKVFPPQVEGGPTVPSPDEPGLPLPGPGPALPTNGAIPIPEPGTAPAVSLMNMDGSVLTMWSRGAGSSLWAYYIGDSNSFGELRNWQIMPGTRPNTIQFRNVDVGTCMTSFPGFKGGVQLSTAPCKFGPERFDFQPMATRNGNYQLKSLSTGLCIRANFLGRTPSSPYATTLTMERCPSSGEKNFEFMWSISEPLRPALATIAKPEIRPFPPQPIEPDEHSTGGEQ |
| 预测分子量 | 29.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于cdtA重组蛋白的3篇模拟参考文献(仅供参考，实际文献需通过学术数据库检索)：
---
1. **标题**: "Cloning and expression of the cdtA gene from *Helicobacter pylori*: functional characterization of the recombinant protein"
**作者**: Smith JL, et al.
**摘要**: 本研究报道了幽门螺杆菌cdtA基因的重组表达与纯化，发现该蛋白与cdtC亚基协同作用可促进毒素复合物进入宿主细胞。通过体外细胞毒性实验证实重组cdtA在诱导细胞周期阻滞中起辅助作用。
2. **标题**: "Structural analysis of the cdtA subunit in the bacterial cytolethal distending toxin complex"
**作者**: Chen R, et al.
**摘要**: 通过X射线晶体学解析了cdtA重组蛋白的三维结构，揭示了其与宿主细胞膜表面受体结合的关键结构域，为理解CDT毒素的致病机制提供了分子基础。
3. **标题**: "Immunogenicity of recombinant cdtA protein as a potential vaccine candidate against *Campylobacter jejuni* infections"
**作者**: Gupta S, et al.
**摘要**: 评估了重组cdtA蛋白在小鼠模型中的免疫保护效果，发现其能诱导特异性抗体反应并降低空肠弯曲菌感染后的肠道病理损伤，提示其作为疫苗组分的潜力。
---
**提示**：以上为模拟摘要，实际文献建议通过PubMed、Google Scholar等平台检索关键词(如"cdtA recombinant protein"或"CDT toxin subunit A")。真实研究多集中于毒素机制、宿主互作及治疗应用领域。
**Background of CdtA Recombinant Protein**
The cytolethal distending toxin (CDT) is a bacterial toxin produced by several Gram-negative pathogens, including *Escherichia coli*, *Campylobacter spp.*, and *Haemophilus ducreyi*. It belongs to the AB toxin family, characterized by a bipartite structure: the "A" subunit (CdtB) exerts enzymatic activity, while the "B" subunits (CdtA and CdtC) facilitate cellular binding and delivery of CdtB into host cells. CdtA, a critical component of the toxin complex, plays a role in recognizing and adhering to specific host cell surface receptors, such as cholesterol-rich membrane microdomains or glycosphingolipids, enabling toxin internalization.
Recombinant CdtA protein is generated through molecular cloning techniques, where the *cdtA* gene is expressed in heterologous systems like *E. coli* or insect cells. This allows for large-scale production of purified CdtA for functional and structural studies. Researchers utilize recombinant CdtA to dissect its role in toxin assembly, host cell targeting, and synergy with CdtB/CdtC. Studies have shown that CdtA, though non-toxic alone, is essential for the holotoxin’s ability to induce cell cycle arrest and apoptosis in eukaryotic cells, typically by facilitating the delivery of CdtB, a DNase that causes DNA damage.
Interest in recombinant CdtA also stems from its potential applications in vaccine development and therapeutic inhibition. For instance, antibodies targeting CdtA can neutralize CDT activity, offering a strategy to combat infections caused by CDT-producing pathogens. Additionally, structural analyses of recombinant CdtA have provided insights into its receptor-binding domains, aiding the design of anti-adhesion therapies. However, challenges remain, such as understanding strain-specific variations in CdtA and its interactions with diverse host tissues. Overall, recombinant CdtA serves as a vital tool for unraveling CDT-mediated pathogenesis and advancing antimicrobial strategies.
×
